Topoisomerase II inhibitor 18_product_DataBase

Bioactivity	Topoisomerase II inhibitor 18 (Compound IV) is a Quinoxaline derivative, which inhibits topoisomerase II with IC50 of 7.5 μM. Topoisomerase II inhibitor 18 inhibits proliferation, cell cycle at S phase and induces apoptosis in PC-3 cells. Topoisomerase II inhibitor 18 reveals antitumor activity against cancer[1].
Invitro	Topoisomerase II inhibitor 18 (0-100 μM) 抑制癌细胞 PC-3 和 HepG2 的增殖，IC50 分别为 2.11 和 11.03 μM，对正常细胞 Vero 没有表现出明显的细胞毒性 (IC50 为 23.12 μM)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Topoisomerase II inhibitor 18 相关抗体: Western Blot Analysis[1] Cell Line:
In Vivo	Topoisomerase II inhibitor 18 (5 mg/kg，肌肉注射 21 天) 在 albino 小鼠 Ehrlich 实体肿瘤模型中具有抗肿瘤活性，并具有肾保护作用[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	2382959-65-9
Formula	C20H21N3OS
Molar Mass	351.47
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Elsakka MEG, et al., A quinoxaline-based derivative exhibited potent and selective anticancer activity with apoptosis induction in PC-3 cells through Topo II inhibition. J Biomol Struct Dyn. 2024 Mar 14:1-19.

PeptideDB